Company News For Dec 14, 2017

Zacks Equity Research Published on December 14, 2017

Shares of Civitas Solutions Inc (CIVI - Free Report) declined 10% after reporting fourth quarter 2017 revenues of $380 million, lower than the Zacks Consensus Estimate of $388 million
Cellectis S.A.’s (CLLS - Free Report) shares gained 11.6% after reporting positive results from 2 acute lymphoblastic leukemia trials of Servier and Pfizer's UCART19 product
Shares of VeriFone Systems, Inc. (PAY - Free Report) declined 3.8% after the company issued FY 2018 EPS guidance in the range of $1.47-$1.50 per share, lower than the Zacks Consensus Estimate of $1.57
Finisar Corporation’s gained 22.8% after the company announced that it would receive a $390 million award from Apple (AAPL - Free Report)

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.